Comparison between patients with inactive versus active disease during the last quarter of the first year in ICON
| Continuously ID from months 9 to 12 | Not continuously ID disease from months 9 to 12 | Multivariate | |||
|---|---|---|---|---|---|
| OR | 95% CI | p Value | |||
| Female/male, n (%) | 183 (66.3)/93 (33.7) | 274 (65.4)/145 (34.6) | 1.27 | 0.88 to 1.84 | 0.198 |
| Age at symptom onset Median in years (IQR) | 4.5 (2.5–9.2) | 6.6 (2.9–11.1) | 0.96 | 0.92 to 1.00 | 0.040 |
| Time from symptom onset to diagnosis Median in months (IQR) | 2.0 (1.0–5.0) | 3.0 (1.0–7.0) | 0.97 | 0.95 to 0.99 | 0.014 |
| JIA category, n (%) | |||||
| Oligoarthritis, persistent | 100 (36.2) | 148 (35.4) | 1.00 | – | |
| Oligoarthritis, extended | 25 (9.1) | 40 (9.5) | 1.04 | 0.58 to 1.83 | 0.898 |
| Polyarthritis RF negative | 80 (29.0) | 115 (27.5) | 1.36 | 0.90 to 2.06 | 0.143 |
| Polyarthritis RF positive | 5 (1.8) | 5 (1.2) | 4.46 | 0.74 to 32.24 | 0.113 |
| Psoriatic arthritis | 8 (2.9) | 20 (4.8) | 0.84 | 0.34 to 1.91 | 0.682 |
| Enthesitis-related arthritis | 21 (7.6) | 53 (12.7) | 0.87 | 0.41 to 1.81 | 0.723 |
| Systemic arthritis | 16 (5.8) | 9 (2.2) | 3.35 | 1.37 to 8.67 | 0.001 |
| Undifferentiated arthritis | 21 (7.6) | 29 (6.9) | 1.49 | 0.73 to 3.00 | 0.266 |
| ANA positive, n (% tested) | 176 (65.4) | 217 (54.8) | 1.51 | 1.04 to 2.20 | 0.029 |
| RF positive, n (% tested) | 7 (3.2) | 14 (4.1) | 0.55 | 0.12 to 1.98 | 0.392 |
| HLA-B27 positive, n (% tested) | 36 (18.4) | 70 (21.2) | 1.21 | 0.69 to 2.11 | 0.511 |
Significant p values (<0.05) are shown in bold.
ANA, antinuclear antibodies, HLA B27, human leucocyte antigen B27; ID, inactive disease; JIA, juvenile idiopathic arthritis; RF, rheumatoid factor.